drugset / Trial / NCT00003229

Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal

NCT00003229

RandomizedTreatment

Summary

RATIONALE: Vaccines made from a person's white blood cells and melanoma cells may make the body build an immune response and kill the tumor cells. PURPOSE: Randomized phase I/II trial to study the effectiveness of vaccine therapy made from white blood cells and melanoma cells in treating patients with metastatic melanoma who are undergoing surgery for lymph node and tumor removal.

Timeline

Start
1997-07
Primary completion
2000-04
Completion
2005-02

Drugs

EvaluationDrugModalityDoseRoute
Subject gp100 antigen Peptide Intravenous
Subject tyrosinase peptide Peptide Intravenous
Background aldesleukin Protein / enzyme biologic Subcutaneous

Indications